LOTTE Biologics Secures First Commercial Deal for 120,000-Liter Songdo Plant in South Korea

project_news

LOTTE Biologics Secures First Commercial Deal for 120,000-Liter Songdo Plant in South Korea

Updated on Nov 17, 2026, 09:25 PM IST
Written & Edited by Harikesh VA

LOTTE Biologics, led by Co-CEOs James Park and Yoo-yeol Shin, announced a major commercial manufacturing agreement with a global pharmaceutical company, marking what the company describes as a significant milestone in the commercialization of its Songdo Bio Campus.

 

The deal is the first major commercial manufacturing commitment secured for Songdo Plant 1, and it was finalized ahead of the facility's operational launch.

Deal Terms

Under the terms of the partnership, LOTTE Biologics will provide integrated drug substance and drug product manufacturing services for key products in the customer's portfolio.

 

Commercial production under the agreement is targeted to begin in 2027.

 

Commercial Volume Secured While the Facility Is Still Under Development

The fact that the company has secured commercial manufacturing volume while the facility is still under development is presented by LOTTE Biologics as evidence of customer confidence in its technical expertise, execution capabilities, and long-term supply reliability.

 

The company states that by aligning its capacity expansion with customer commitments from the outset, it is accelerating its path to commercialization and establishing a foundation for sustainable growth.

The agreement translates the company's strategic investment into commercial commitments and, in the company's framing, reinforces its long-term growth trajectory as it works to build a differentiated global contract development and manufacturing organization.

Trusted by Leading EPCs & Manufacturers

Find the Latest Pharmaceutical Plant Projects in South Korea

Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information

Request Free Trial → Learn More →

No credit card Up-to-date coverage

 

Songdo Plant 1: Capacity and Infrastructure

Songdo Plant 1 is designed to meet the evolving demands of global biopharmaceutical manufacturing. The facility features state-of-the-art production infrastructure, advanced automation, and large-scale cold-chain warehousing intended to support efficient, reliable, and quality-driven operations.

The broader Songdo Bio Campus is being developed with a planned capacity of 360,000 liters across three plants. Plant 1 itself will provide 120,000 liters of capacity through eight 15,000-liter stainless-steel bioreactors.

An Integrated Network Anchored by Syracuse

The Songdo facility will complement LOTTE Biologics' established Syracuse Bio Campus in New York. According to the company, the Syracuse site brings more than two decades of manufacturing experience and a track record of supporting over 62 regulatory approvals. The site also recently completed a US Food and Drug Administration inspection with zero observations.

Together, the two campuses form an integrated global manufacturing network that the company says is designed to deliver operational flexibility, consistent quality standards, and greater supply chain resilience.

Positioning Within a Competitive CDMO Landscape

LOTTE Biologics frames the deal in the context of broader industry dynamics, noting that pharmaceutical companies are increasingly seeking trusted manufacturing partners with proven execution capabilities and geographically diversified supply networks.

 

Against that backdrop, the company is positioning itself as a compelling partner for global biologics manufacturing, and it describes the new agreement as a tangible step toward that ambition.

Leadership Commentary

James Park, Co-CEO of LOTTE Biologics, commented on the announcement: "This agreement is a strong endorsement of our strategy and the confidence our customers place in LOTTE Biologics. We are not simply building manufacturing capacity. We are building a globally integrated platform designed to deliver quality, reliability, and speed. By combining Syracuse's proven expertise with Songdo's advanced infrastructure, we are well positioned to support our partners' success and bring life-changing medicines to patients worldwide."

Identity Remains Undisclosed

The identity of the global pharmaceutical company behind the new agreement was not disclosed in the announcement.

 

What is confirmed is the scope of the engagement, integrated drug substance and drug product manufacturing for key products in the customer's portfolio, and the timeline, with commercial production targeted to begin in 2027, the year after the agreement was signed.

What the Deal Means for Songdo Bio Campus

With the first major commercial commitment now in place before Plant 1 even begins operations, the Songdo Bio Campus enters its launch phase with anchored demand.

 

The campus's planned build-out of 360,000 liters across three plants, beginning with Plant 1's 120,000 liters, proceeds alongside a Syracuse operation that the company cites as proof of its regulatory and manufacturing record: more than two decades of experience, support for over 62 regulatory approvals, and a recent FDA inspection completed with zero observations.

For LOTTE Biologics, the company characterizes the agreement as validation of its strategy and a step in building a globally integrated platform, one that pairs the proven expertise of its New York operations with the advanced infrastructure of its new South Korean site in service of global biologics supply.

Stay Ahead of South Korea's Next Major Chemical Sector Developments

Consider this: while some teams scramble to react to chemical project announcements after the news breaks, others are already positioned to bid, partner, or supply. The difference? Access to structured, timely project intelligence across South Korea's chemical industry.

 

The Global Project Tracking (GPT) platform by Blackridge Research consolidates development activity from across South Korea's vibrant chemical sector, from production facilities to innovative projects, into one actionable dashboard.

 

Whether your focus is identifying early-stage opportunities in the chemical sector or monitoring competitors' project pipelines, the platform is designed to eliminate uncertainty in regional expansion planning.

 

  • Upcoming Projects

  • Tender Notices

  • Contract Awards

  • Projects Under Construction

  • Completed Projects

 

Schedule a Free Demo to discover how the Global Project Tracking (GPT) platform by Blackridge Research can provide your team with a competitive advantage in the South Korean chemical sector.

Tags

Leave a Comment

We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.

We read every comment and do our best to respond to them all.

Protected by Cloudflare Turnstile